News & Events

Speak with a Scientist

<!–[if lte IE 8]>

<script charset=”utf-8″ type=”text/javascript” src=”//js.hsforms.net/forms/v2-legacy.js“></script>

<![endif]–>

<script charset=”utf-8″ type=”text/javascript” src=”//js.hsforms.net/forms/v2.js“></script>

<script>

hbspt.forms.create({

portalId: “2932238”,

formId: “1a9c125c-1418-4756-aa78-c588be1598a5”

});

</script>

Subscribe to Newsletter

<!–[if lte IE 8]>

<script charset=”utf-8″ type=”text/javascript” src=”//js.hsforms.net/forms/v2-legacy.js”></script>

<![endif]–>

<script charset=”utf-8″ type=”text/javascript” src=”//js.hsforms.net/forms/v2.js”></script>

<script>

hbspt.forms.create({

portalId: “2932238”,

formId: “68e10107-e21f-48d8-bc30-ae10ff4ffed7”

});

</script>

Cellaria Inc. partners with researchers at Northeastern University to advance new photomedicine therapies for key cancers

Successful award of NIH R01 funding paves the way for accelerated Precision Therapeutics.

11/17/2020 WAKEFIELD, MA: ​Cellaria Inc (Wakefield, MA, USA) and the Spring Lab, Northeastern University, announce the successful receipt of a National Institutes of Health (NIH) R01 grant to extend and advance the application of innovative new photomedicine-based therapies for hard-to-treat cancers. The grant highlights the close working relationship of the two organizations and will provide $3.2M funding to develop precision therapeutics closely tailored to the requirements of specific patient populations. Cellaria’s contribution to the partnership is next generation, patient-derived, customized cell models that boost the effectiveness of ​in vitro studies, helping researchers to identify where the technology can have the most impact. Dr Bryan Spring, Assistant Professor of Biomedical Physics credits Cellaria with a vital role in accelerating his research.

“We’ve demonstrated proof of concept and seen significant interest from clinicians,” said Dr Spring. “However, we initially targeted just a single ovarian cancer biomarker. To capture the heterogeneity of the disease and efficiently study multiple biomarkers we needed to upgrade our cell models. Developing new models in-house would have taken years and instead we chose to work with Cellaria. This has really accelerated progress by providing rapid access to rigorously characterized cell models for specific molecular subtypes and patient populations.”

Dr Spring’s research focuses on the use of antibody-photosensitizer conjugates to make cancer cells susceptible to light-induced destruction, targeting microscopic cancer cell deposits left behind by conventional therapies. Primary areas of application are pancreatic and ovarian cancer. With these cancers, cells left behind by surgery and other conventional therapies can metastasize in the peritoneal cavity and abdomen, attacking other organs and increasing the severity of the disease. The new NIH research grant is entitled “Multiplexed and dynamically targeted photoimmunotherapy of heterogeneous, chemoresistant micrometastases guided by online in vivo optical imaging of cell-surface biomarkers”.

Cellaria provides cell models, complete with comprehensive omics data, that help the researchers to determine which biomarkers are most actionable when it comes to targeting drug resistant cells and applying the photomedicine. These cell models robustly represent the full heterogeneity of the cancers, which is essential for the development of precision therapies. Dr Spring has been using Powder, a high grade serous ovarian cancer cell model developed from the carcinoma of a 65 – 69 Caucasian, stage IV patient. New models for pancreatic cancer have recently been added to the Cellaria portfolio. All have a robustly authenticated lineage and are provided with protocols to maintain specific biomarker expression. Cellaria’s unrivalled expertise in cell line growth, stabilization and characterization underpin the company’s ability to supply customised models that enable researchers to identify the specific biomarkers of most relevance to their work.

“Cellaria have all the -omics in place and are highly responsive in terms of refining models to our requirements,” said Dr Spring. “The Cellaria team are experts in their field and great to work with. The bottom line is that via this collaboration we get to concentrate on our science, rather than the tools we need to support it, which is just as we prefer it.”

About Cellaria Inc.

Cellaria Inc’s mission is to develop and build more informative disease cell models to revolutionize and accelerate the search for a cure. The company provides a suite of products and services that are actionable, replicable and that originate from a patient’s unique specimens. ​With 7 years of research and development, Cellaria’s solutions better enable disease researchers to select promising compounds and ultimately identify the most effective treatment for each patient’s needs. This helps lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure and/or personalized treatments.

Data Demonstrating Power of Metastatic Niche and Patient-Specific Models in Oncology Drug Screening Studies Presented at 2020 AACR Virtual Annual Meeting II

First presentation of data using Cellaria’s proprietary patient-specific models of the tumor microenvironment used to study tumor growth, metastasis.

06/24/2020 WAKEFIELD, MA: Cellaria announces today it is presenting data on the value of modeling the metastatic niche, and the benefits of using patient-derived cancer cell models, mesenchymal stem cells (MSCs), and optimization of oxygen level and extracellular matrix (ECM) to study antitumor drug response, personalized therapy, and disease mechanisms. The data, featured in a poster at 2020 AACR Annual Meeting II, results from Cellaria’s spheroid system using five cancer cell models (pancreatic, lung adenocarcinoma, colon adenocarcinoma, endometrioid ovarian and high-grade serous carcinoma). With this 3D system, Cellaria is addressing an unmet need to improve predictions of the safety and efficacy of new drugs in preclinical testing and clinical trials.

By using patient-specific cell models, translational scientists are able to go beyond traditional cell lines, to address the complexity and individuality of the disease and identify treatments that better meet the needs of each patient.  Specificity in cell models enables researchers to derive the answers they need earlier in the drug development life cycle and with a continuous, direct connection to the patient.

“This data demonstrates the power of using patient specific cell models in a 3D format to model the tumor microenvironment and gain more actionable information from drug screening studies” comments David Deems, CEO, Cellaria Inc. “By using specific model patient populations that maintain their heterogeneity and individuality, users can test targets on our highly characterized cell models and select the mutation profile that is most important to their research.”

To see the data, please download the poster here. For more information on Cellaria Inc and its patient-specific cell models, please visit cellariainc.com or call 978-720-8051.

 

Download the Poster

 

About Cellaria Inc.

Cellaria Inc’s mission is to develop and build more informative disease cell models to revolutionize and accelerate the search for a cure. The company provides a suite of products and services that are actionable, replicable and that originate from a patient’s unique specimens. Cellaria’s solutions better enable disease researchers to select promising compounds and ultimately identify the most effective treatment for each patient’s needs. This helps lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure and/or personalized treatments.

Cellaria Forms Collaborative Partnership with SBH Sciences

Cambridge, Mass. and Natick, Mass., May 02, 2018 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the formation of a strategic partnership with SBH Sciences (SBH). The companies will collaborate to evaluate drug response using Cellaria’s patient-specific cell models and cell culture media products with SBH’s cell-based assay services. As a result, SBH will be able to accelerate its efforts to generate drug response data for larger sets of patients that are clinically diagnosed with the same disease.

Cellaria and Biological Industries USA Partner on Stem Cell Media and Research

CAMBRIDGE, Mass. and CROMWELL, Conn., May 04, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific models for challenging diseases, and Biological Industries USA (BI-USA), a subsidiary of Biological Industries (Israel), today announced a new sales and marketing agreement to promote custom stem cell services. The partnership combines BI-USA’s strength in stem cell culture media and manufacturing with Cellaria’s comprehensive Stem Cell Services program, which includes industry leading RNA reprogramming and custom differentiation services.

Cellaria Adds Next-Generation RNA Reprogramming and Stem Cell Services

CAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the expansion of its offerings to include a suite of stem cell services. The initiative advances Cellaria’s mission to provide more accurate patient and disease-specific cell models to help researchers focus and accelerate their research and discovery efforts.

Cellaria Forms Strategic Partnership with AMS Biotechnology

CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the formation of a strategic partnership with AMS Biotechnology (AMSBIO). As part of the agreement, AMSBIO will distribute, market and sell Cellaria cell models and culture media throughout Europe. The partnership enables Cellaria to better meet growing demand for its products outside the US.

Connect With Us

Learn more about how Cellaria can help transform your research efficacy.

Speak to a scientist or have a general inquiry

To help us better serve you, please provide a few more pieces of information:

Subscribe to Cellaria emails

Get the latest news on Cellaria's products, services, and events.

To help us better serve you, please provide a few more pieces of information: